|
1.
|
Nebert DW, Zhang G, Vesell ES. Genetic risk prediction: individualized variability in susceptibility to toxicants. Annu Rev Pharmacol Toxicol. 2013 Jan 6; 53:355-75.
|
|
|
|
|
2.
|
Berlin CM, Paul IM, Vesell ES. Safety issues of maternal drug therapy during breastfeeding. Clin Pharmacol Ther. 2009 Jan; 85(1):20-2.
|
|
|
|
|
3.
|
Mandel HG, Vesell ES. Declines in NIH R01 research grant funding. Science. 2008 Oct 10; 322(5899):189.
|
|
|
|
|
4.
|
Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008; 40(2):187-224.
|
|
|
|
|
5.
|
Spector R, Vesell ES. Pharmacology and statistics: recommendations to strengthen a productive partnership. Pharmacology. 2006; 78(3):113-22.
|
|
|
|
|
6.
|
Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci. 2006 Nov; 27(11):580-6.
|
|
|
|
|
7.
|
Mandel HG, Vesell ES. Declines in funding of NIH R01 research grants. Science. 2006 Sep 8; 313(5792):1387-8.
|
|
|
|
|
8.
|
Spector R, Vesell ES. The heart of drug discovery and development: rational target selection. Pharmacology. 2006; 77(2):85-92.
|
|
|
|
|
9.
|
Spector R, Vesell ES. The power of pharmacological sciences: the example of proton pump inhibitors. Pharmacology. 2006; 76(3):148-55; discussion 156.
|
|
|
|
|
10.
|
Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol. 2004 Oct 1; 500(1-3):267-80.
|
|
|
|
|
11.
|
Mandel HG, Vesell ES. From progress to regression: biomedical research funding. J Clin Invest. 2004 Oct; 114(7):872-6.
|
|
|
|
|
12.
|
Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics. 2003; 3(6):361-70.
|
|
|
|
|
13.
|
Vesell ES. Recollections from the Kunkel laboratory, 1956-1958. Lupus. 2003; 12(3):238-41.
|
|
|
|
|
14.
|
Berlin CM, LaKind JS, Sonawane BR, Kacew S, Borgert CJ, Bates MN, Birnbach N, Campbell R, Dermer A, Dewey KG, Ellerbee SM, Fürst P, Giacoia GP, Gartner L, Groer M, Haynes SG, Humerick SS, Lawrence RA, Lorber M, Lovelady C, Mason A, Needham LL, Picciano MF, Plautz J, Ryan JJ, Selevan SG, Sumaya CV, Tully MR, Uhl K, Vesell E, Wilson JT. Conclusions, research needs, and recommendations of the expert panel: technical workshop on human milk surveillance and research for environmental chemicals in the United States. J Toxicol Environ Health A. 2002 Nov 22; 65(22):1929-35.
|
|
|
|
|
15.
|
Spector R, Vesell ES. Which studies of therapy merit credence? Vitamin E and estrogen therapy as cautionary examples. J Clin Pharmacol. 2002 Sep; 42(9):955-62.
|
|
|
|
|
16.
|
Spector R, Vesell ES. A rational approach to the selection of useful drugs for clinical practice. Pharmacology. 2002 May; 65(2):57-61.
|
|
|
|
|
17.
|
Mandel HG, Vesell ES. NIH budget grows, but not R01 success rates. Science. 2001 Oct 5; 294(5540):54-7.
|
|
|
|
|
18.
|
Spector R, Vesell ES. The pursuit of clinical truth: role of epidemiology/observation studies. J Clin Pharmacol. 2000 Nov; 40(11):1205-10.
|
|
|
|
|
19.
|
Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol. 2000 Sep; 40(9):930-8.
|
|
|
|
|
20.
|
Vesell ES, Beyer KH. Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. Toxicology. 2000 Apr 3; 144(1-3):5-11.
|
|
|
|
|
21.
|
Schmucker DL, Vesell ES. Are the elderly underrepresented in clinical drug trials? J Clin Pharmacol. 1999 Nov; 39(11):1103-8.
|
|
|
|
|
22.
|
Mandel HG, Vesell ES. Likelihood of NIH extramural funding. Science. 1999 Sep 10; 285(5434):1674-6.
|
|
|
|
|
23.
|
Meger M, Richter E, Zwickenpflug W, Oehlmann C, Hargaden MB, A-Rahim YI, Vesell ES. Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in rhesus monkeys. Drug Metab Dispos. 1999 Apr; 27(4):471-8.
|
|
|
|
|
24.
|
Vesell ES, Beyer KH. Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects. Pharmacology. 1999 Mar; 58(3):140-6.
|
|
|
|
|
25.
|
Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998 Sep 18; 281(5384):1820-1.
|
|
|
|
|
26.
|
Ahsan N, Korsunsky Z, Beyer KH, Vesell ES. Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study. Pharmacology. 1998 Aug; 57(2):96-103.
|
|
|
|
|
27.
|
Vesell ES, Korsunsky Z. Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone. Pharmacology. 1998 May; 56(5):262-6.
|
|
|
|
|
28.
|
Follansbee MH, Beyer KH, Griffith JW, Vesell ES. Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats. Pharmacology. 1997 May; 54(5):241-55.
|
|
|
|
|
29.
|
Follansbee MH, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats. Pharmacology. 1997 May; 54(5):256-60.
|
|
|
|
|
30.
|
Vesell ES. Therapeutic lessons from pharmacogenetics. Ann Intern Med. 1997 Apr 15; 126(8):653-5.
|
|
|
|
|
31.
|
Korrapati MR, Sorkin JD, Andres R, Muller DC, Loi CM, Vesell ES, Vestal RE. Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging. J Clin Pharmacol. 1997 Feb; 37(2):83-91.
|
|
|
|
|
32.
|
Vesell ES. Reflections from distant cuvettes. Drug Metab Rev. 1996 Nov; 28(4):493-511.
|
|
|
|
|
33.
|
A-Rahim YI, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes. Pharmacology. 1996 Oct; 53(4):197-210.
|
|
|
|
|
34.
|
A-Rahim YI, Rannels SL, Kimball SR, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver. Pharmacology. 1996 Oct; 53(4):211-8.
|
|
|
|
|
35.
|
A-Rahim YI, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats. Pharmacology. 1996 Mar; 52(3):135-44.
|
|
|
|
|
36.
|
A-Rahim YI, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats. Pharmacology. 1996 Mar; 52(3):145-52.
|
|
|
|
|
37.
|
Vesell ES, Gaylor DW. Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. Pharmacogenetics. 1995 Feb; 5(1):18-23.
|
|
|
|
|
38.
|
Vesell ES, Seaton TD, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics. 1995 Feb; 5(1):53-7.
|
|
|
|
|
39.
|
Schmucker DL, O'Mahony MS, Vesell ES. Women in clinical drug trials. An update. Clin Pharmacokinet. 1994 Dec; 27(6):411-7.
|
|
|
|
|
40.
|
Vesell ES, Chambers CE, Seaton TD, Passananti GT, Demers LM, Beyer KH. Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients. J Clin Pharmacol. 1994 Dec; 34(12):1234-45.
|
|
|
|
|
41.
|
Estévez F, De Angelo T, Vesell ES. Basal and paracetamol-depleted glutathione from human lymphocytes: ethnic variability. Acta Physiol Pharmacol Ther Latinoam. 1994; 44(1-2):48-54.
|
|
|
|
|
42.
|
Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES. Nicotine metabolism in cigarette smokers and nonsmokers. Clin Pharmacol Ther. 1994 Jan; 55(1):84-7.
|
|
|
|
|
43.
|
Seaton MJ, Vesell ES. Variables affecting nicotine metabolism. Pharmacol Ther. 1993 Dec; 60(3):461-500.
|
|
|
|
|
44.
|
Seaton MJ, Vesell ES, Luo H, Hawes EM. Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. J Chromatogr. 1993 Nov 17; 621(1):49-53.
|
|
|
|
|
45.
|
Vesell ES, Chambers CE, Passananti GT, Demers LM, Beyer KH. Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus. J Clin Pharmacol. 1993 Sep; 33(9):823-31.
|
|
|
|
|
46.
|
Seaton MJ, Kyerematen GA, Vesell ES. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile. Drug Metab Dispos. 1993 Sep-Oct; 21(5):927-32.
|
|
|
|
|
47.
|
Vesell ES, DeAngelo TM, Katz IR. Reproducibility of antipyrine half-lives in elderly subjects. Clin Pharmacol Ther. 1993 Aug; 54(2):150-7.
|
|
|
|
|
48.
|
Schmucker DL, Vesell ES. Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther. 1993 Jul; 54(1):11-5.
|
|
|
|
|
49.
|
Beyer KH, Ward TD, Vary JE, Gelarden RT, Knutson DW, Vesell ES. Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency. J Clin Pharmacol. 1993 Jun; 33(6):554-61.
|
|
|
|
|
50.
|
Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH. Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects. J Clin Pharmacol. 1992 Dec; 32(12):1128-34.
|
|
|
|
|
51.
|
Miele ME, Vesell ES, Ehmann WC, Lipton A, Harvey H, Kan NC. Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1992 Nov; 65(2):183-92.
|
|
|
|
|
52.
|
Mandel HG, Woosley RL, Vesell ES. Biomedical research funding: view of the National Caucus of Basic Biomedical Science Chairs. FASEB J. 1992 Oct; 6(13):3133-4.
|
|
|
|
|
53.
|
Houck JR, Romano PJ, Bartholomew M, Smith PJ, Kloszewski F, Vesell ES. Do histocompatibility antigens influence the risk of head and neck carcinoma? Cancer. 1992 May 1; 69(9):2327-32.
|
|
|
|
|
54.
|
Passananti GT, Vesell ES, Jeszenka EV, Gelarden RT, Beyer KH. Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. Pharmacology. 1992; 45(3):129-41.
|
|
|
|
|
55.
|
Beyer KH, Gelarden RT, Vesell ES. Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs. Pharmacology. 1992; 44(3):124-38.
|
|
|
|
|
56.
|
Seaton M, Kyerematen GA, Morgan M, Jeszenka EV, Vesell ES. Nicotine metabolism in stumptailed macaques, Macaca arctoides. Drug Metab Dispos. 1991 Sep-Oct; 19(5):946-54.
|
|
|
|
|
57.
|
Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther. 1991 Sep; 50(3):239-48.
|
|
|
|
|
58.
|
Romano PJ, Bartholomew M, Smith PJ, Kloszewski F, Stryker J, Houck J, Vesell ES. HLA antigens influence resistance to lung carcinoma. Hum Immunol. 1991 Aug; 31(4):236-40.
|
|
|
|
|
59.
|
Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology. 1991 May; 13(5):941-6.
|
|
|
|
|
60.
|
Vesell ES. Genetic and environmental factors causing variation in drug response. Mutat Res. 1991 Apr; 247(2):241-57.
|
|
|
|
|
61.
|
Vesell ES, Mandel HG, Brody TM, Greenbaum LM, Roberts J, Standaert FG. A committee report on vacant chairs of pharmacology. Acad Med. 1991 Feb; 66(2):93.
|
|
|
|
|
62.
|
Vesell ES. Genetic factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. Ann Genet. 1991; 34(3-4):167-72.
|
|
|
|
|
63.
|
Kyerematen GA, Vesell ES. Metabolism of nicotine. Drug Metab Rev. 1991; 23(1-2):3-41.
|
|
|
|
|
64.
|
Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther. 1990 Dec; 48(6):641-51.
|
|
|
|
|
65.
|
Kyerematen GA, Morgan M, Warner G, Martin LF, Vesell ES. Metabolism of nicotine by hepatocytes. Biochem Pharmacol. 1990 Oct 15; 40(8):1747-56.
|
|
|
|
|
66.
|
McManus KT, deBethizy JD, Garteiz DA, Kyerematen GA, Vesell ES. A new quantitative thermospray LC-MS method for nicotine and its metabolites in biological fluids. J Chromatogr Sci. 1990 Oct; 28(10):510-6.
|
|
|
|
|
67.
|
Doolittle DJ, Rahn CA, Riccio E, Passananti GT, Howard G, Vesell ES, Burger GT, Hayes AW. Comparative studies of the mutagenicity of urine from smokers and non-smokers on a controlled non-mutagenic diet. Food Chem Toxicol. 1990 Sep; 28(9):639-46.
|
|
|
|
|
68.
|
Beyer KH, Gelarden RT, Vary JE, Brown LE, Vesell ES. Novel multivalent effects of pyrazinoylguanidine in patients with azotemia. Clin Pharmacol Ther. 1990 May; 47(5):629-38.
|
|
|
|
|
69.
|
Passananti GT, Wolff CA, Vesell ES. Reproducibility of individual rates of ethanol metabolism in fasting subjects. Clin Pharmacol Ther. 1990 Mar; 47(3):389-96.
|
|
|
|
|
70.
|
Norris KK, DeAngelo TM, Vesell ES. Genetic and environmental factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. J Clin Invest. 1989 Dec; 84(6):1749-56.
|
|
|
|
|
71.
|
Doolittle DJ, Rahn CA, Burger GT, Lee CK, Reed B, Riccio E, Howard G, Passananti GT, Vesell ES, Hayes AW. Effect of cooking methods on the mutagenicity of food and on urinary mutagenicity of human consumers. Food Chem Toxicol. 1989 Oct; 27(10):657-66.
|
|
|
|
|
72.
|
Mandel HG, Vesell ES. NIH funding. FASEB J. 1989 Sep; 3(11):2322-3.
|
|
|
|
|
73.
|
Vickers FF, Bowman TA, Dvorchik BH, Passananti GT, Hughes DM, Vesell ES. On the antipyrine test in laboratory animals. Studies in the dog and monkey. Drug Metab Dispos. 1989 Mar-Apr; 17(2):160-5.
|
|
|
|
|
74.
|
Denlinger CL, Vesell ES. Hormonal regulation of the developmental pattern of epoxide hydrolases. Studies in rat liver. Biochem Pharmacol. 1989 Feb 15; 38(4):603-10.
|
|
|
|
|
75.
|
Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther. 1989; 41(3):535-52.
|
|
|
|
|
76.
|
Costa E, Karczmar AG, Vesell ES. Bernard B. Brodie and the rise of chemical pharmacology. Annu Rev Pharmacol Toxicol. 1989; 29:1-21.
|
|
|
|
|
77.
|
Vesell ES, Heubel F, Netter KJ. Brief maternal deprivation of rats reduces hepatic mixed function oxidase activities. Life Sci. 1989; 45(19):1755-61.
|
|
|
|
|
78.
|
Kyerematen GA, Owens GF, Chattopadhyay B, deBethizy JD, Vesell ES. Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. Drug Metab Dispos. 1988 Nov-Dec; 16(6):823-8.
|
|
|
|
|
79.
|
Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988 Apr; 43(4):345-53.
|
|
|
|
|
80.
|
Kyerematen GA, Taylor LH, deBethizy JD, Vesell ES. Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos. 1988 Jan-Feb; 16(1):125-9.
|
|
|
|
|
81.
|
Kyerematen GA, Taylor LH, deBethizy JD, Vesell ES. Radiometric-high-performance liquid chromatographic assay for nicotine and twelve of its metabolites. J Chromatogr. 1987 Aug 7; 419:191-203.
|
|
|
|
|
82.
|
Vesell ES. Pharmacogenetic perspectives on susceptibility to toxic industrial chemicals. Br J Ind Med. 1987 Aug; 44(8):505-9.
|
|
|
|
|
83.
|
Slusher LB, Park SS, Gelboin HV, Vesell ES. Studies on the metabolism of aminopyrine, antipyrine and theophylline using monoclonal antibodies to cytochrome P-450 isozymes purified from rat liver. Biochem Pharmacol. 1987 Jul 15; 36(14):2359-67.
|
|
|
|
|
84.
|
Fabisiak JP, Vesell ES, Rannels DE. Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. I. Analysis, characterization and regulation of specific beta adrenergic receptors. J Pharmacol Exp Ther. 1987 May; 241(2):722-7.
|
|
|
|
|
85.
|
Fabisiak JP, Vesell ES, Rannels DE. Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. II. Receptor-independent accumulation of beta adrenergic antagonists and other cationic amphiphilic drugs in lamellar bodies. J Pharmacol Exp Ther. 1987 May; 241(2):728-35.
|
|
|
|
|
86.
|
Denlinger CL, Stryker KK, Slusher LB, Vesell ES. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine. Clin Pharmacol Ther. 1987 May; 41(5):522-30.
|
|
|
|
|
87.
|
Shively CA, Vesell ES. In vivo and in vitro biotransformation of theobromine by phenobarbital- and 3-methylcholanthrene-inducible cytochrome P-450 monooxygenases in rat liver. Role of thiol compounds. Drug Metab Dispos. 1987 Mar-Apr; 15(2):217-24.
|
|
|
|
|
88.
|
Kimberling WJ, Goldgar DE, Penno MB, Vesell ES. Pharmacogenetic application of methods from population genetics. Clin Pharmacol Ther. 1987 Jan; 41(1):3-10.
|
|
|
|
|
89.
|
Fabisiak JP, Rannels SR, Vesell ES, Rannels DE. Receptor-independent sequestration of beta-adrenergic ligands by alveolar type II cells. Am J Physiol. 1986 Jun; 250(6 Pt 1):C871-9.
|
|
|
|
|
90.
|
Vesell ES. Polymorphisms of antipyrine and theophylline metabolism in man: molecular and clinical implications. Xenobiotica. 1986 May; 16(5):401-20.
|
|
|
|
|
91.
|
Vesell ES. Dynamic interactions among host factors that influence antipyrine metabolism: implications for the design and interpretation of studies on ethnic pharmacokinetic variations. Prog Clin Biol Res. 1986; 214:425-51.
|
|
|
|
|
92.
|
Vesell ES. Complex interactions between drugs and dietary factors. NIDA Res Monogr. 1986; 68:89-109.
|
|
|
|
|
93.
|
Vesell ES. Pharmacogenetic approaches to the prediction of drug response. NIDA Res Monogr. 1986; 66:25-40.
|
|
|
|
|
94.
|
Vesell ES. Implications for risk assessment of host factors causing large pharmacokinetic variations. Toxicol Ind Health. 1985 Dec; 1(4):135-52.
|
|
|
|
|
95.
|
Vesell ES. Clinical pharmacology: a personal perspective. Clin Pharmacol Ther. 1985 Dec; 38(6):603-12.
|
|
|
|
|
96.
|
Vesell ES. Genetic host factors: determinants of drug response. N Engl J Med. 1985 Jul 25; 313(4):261-2.
|
|
|
|
|
97.
|
Miller CA, Slusher LB, Vesell ES. Polymorphism of theophylline metabolism in man. J Clin Invest. 1985 May; 75(5):1415-25.
|
|
|
|
|
98.
|
Vesell ES. Pharmacogenetics and encainide. Hepatology. 1985 May-Jun; 5(3):525.
|
|
|
|
|
99.
|
Shively CA, Tarka SM, Arnaud MJ, Dvorchik BH, Passananti GT, Vesell ES. High levels of methylxanthines in chocolate do not alter theobromine disposition. Clin Pharmacol Ther. 1985 Apr; 37(4):415-24.
|
|
|
|
|
100.
|
Vesell ES, Biebuyck JF. Further comments regarding drug disposition in the surgical patient. Anesthesiology. 1985 Jan; 62(1):95-6.
|
|
|
|
|
101.
|
Nash RM, Stein L, Penno MB, Passananti GT, Vesell ES. Sources of interindividual variations in acetaminophen and antipyrine metabolism. Clin Pharmacol Ther. 1984 Oct; 36(4):417-30.
|
|
|
|
|
102.
|
Vesell ES. Complex effects of diet on drug disposition. Clin Pharmacol Ther. 1984 Sep; 36(3):285-96.
|
|
|
|
|
103.
|
Vesell ES. Pharmacogenetic perspectives: genes, drugs and disease. Hepatology. 1984 Sep-Oct; 4(5):959-65.
|
|
|
|
|
104.
|
Vesell ES, Biebuyck JF. New approaches to assessment of drug disposition in the surgical patient. Anesthesiology. 1984 Jun; 60(6):529-33.
|
|
|
|
|
105.
|
Vesell ES. New directions in pharmacogenetics: Introduction. Fed Proc. 1984 May 15; 43(8):2319-25.
|
|
|
|
|
106.
|
Vesell ES, Penno MB. A new polymorphism of hepatic drug oxidation in humans: family studies of antipyrine metabolites. Fed Proc. 1984 May 15; 43(8):2342-7.
|
|
|
|
|
107.
|
Slusher LB, Vesell ES. Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites. Clin Pharmacol Ther. 1984 May; 35(5):568-75.
|
|
|
|
|
108.
|
Vesell ES. Selection of subjects for investigation of host factors affecting drug response: a method to identify new pharmacogenetic conditions. Clin Pharmacol Ther. 1984 Jan; 35(1):1-11.
|
|
|
|
|
109.
|
Kouri RE, McKinney CE, Levine AS, Edwards BK, Vesell ES, Nebert DW, McLemore TL. Variations in aryl hydrocarbon hydroxylase activities in mitogen-activated human and nonhuman primate lymphocytes. Toxicol Pathol. 1984; 12(1):44-8.
|
|
|
|
|
110.
|
Vesell ES. Noninvasive assessment in vivo of hepatic drug metabolism in health and disease. Ann N Y Acad Sci. 1984; 428:293-307.
|
|
|
|
|
111.
|
Tarka SM, Arnaud MJ, Dvorchik BH, Vesell ES. Theobromine kinetics and metabolic disposition. Clin Pharmacol Ther. 1983 Oct; 34(4):546-55.
|
|
|
|
|
112.
|
Vesell ES, Penno MB. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet. 1983 Sep-Oct; 8(5):378-409.
|
|
|
|
|
113.
|
Penno MB, Vesell ES. Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest. 1983 Jun; 71(6):1698-709.
|
|
|
|
|
114.
|
Kyerematen GA, Passananti GT, Greene FE, Vesell ES. Time-dependent induction of hepatic drug metabolism in rats by cotinine. Life Sci. 1983 Jan 31; 32(5):551-6.
|
|
|
|
|
115.
|
Kyerematen GA, Dvorchik BH, Vesell ES. Influence of different forms of tobacco intake on nicotine elimination in man. Pharmacology. 1983; 26(4):205-9.
|
|
|
|
|
116.
|
Kyerematen GA, Damiano MD, Dvorchik BH, Vesell ES. Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther. 1982 Dec; 32(6):769-80.
|
|
|
|
|
117.
|
Vesell ES, Mandel HG. Crisis in NIH funding. Science. 1982 Feb 26; 215(4536):1026-8.
|
|
|
|
|
118.
|
Vesell ES. On the significance of host factors that affect drug disposition. Clin Pharmacol Ther. 1982 Jan; 31(1):1-7.
|
|
|
|
|
119.
|
Miaskiewicz SL, Shively CA, Vesell ES. Sex differences in absorption kinetics of sodium salicylate. Clin Pharmacol Ther. 1982 Jan; 31(1):30-7.
|
|
|
|
|
120.
|
Berlin CM, Vesell ES. Antipyrine disposition in milk and saliva of lactating women. Clin Pharmacol Ther. 1982 Jan; 31(1):38-44.
|
|
|
|
|
121.
|
Vesell ES. Complex, dynamically interacting host factors that affect the disposition of drugs and carcinogens. IARC Sci Publ. 1982; (39):427-37.
|
|
|
|
|
122.
|
Piroli RJ, Passananti GT, Shively CA, Vesell ES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther. 1981 Dec; 30(6):810-6.
|
|
|
|
|
123.
|
Vesell ES. The influence of host factors on drug response. VII. Implications for interpretation of clinical trials and other published studies on drug response in man. Ration Drug Ther. 1981 Dec; 15(12):1-5.
|
|
|
|
|
124.
|
Vesell ES. The influence of host factors on drug response. VII. Renal diseases. Ration Drug Ther. 1981 Nov; 15(11):1-9.
|
|
|
|
|
125.
|
Kinney EL, Trautmann J, Gold JA, Vesell ES, Zelis R. Underrepresentation of women in new drug trials. Ann Intern Med. 1981 Oct; 95(4):495-9.
|
|
|
|
|
126.
|
Vesell ES. The influence of host factors on drug response. VI. Hepatocellular diseases. Ration Drug Ther. 1981 Aug; 15(8):1-8.
|
|
|
|
|
127.
|
Penno MB, Dvorchik BH, Vesell ES. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci U S A. 1981 Aug; 78(8):5193-6.
|
|
|
|
|
128.
|
Sultatos LG, Liu DK, Vesell ES. Further studies on the increase in drug-metabolizing capacity adjacent to intrahepatic Morris hepatomas. Biochem Pharmacol. 1981 May 1; 30(9):971-8.
|
|
|
|
|
129.
|
Beyer KH, Fehr DM, Gelarden RT, White WJ, Lang CM, Vesell ES. Hydrochlorothiazide-induced 131I excretion facilitated by salt and water. J Clin Pharmacol. 1981 May-Jun; 21(5-6):201-12.
|
|
|
|
|
130.
|
Vesell ES. The influence of host factors on drug response. V. Endocrinological, gastrointestinal, and pulmonary diseases. Ration Drug Ther. 1981 Mar; 15(3):1-6.
|
|
|
|
|
131.
|
Manfredi RL, Vesell ES. Inhibition of theophylline metabolism by long-term allopurinol administration. Clin Pharmacol Ther. 1981 Feb; 29(2):224-9.
|
|
|
|
|
132.
|
Spector R, Roberts R, Vesell ES. Clinical pharmacology: a new specialty. Am J Med. 1981 Feb; 70(2):221-2.
|
|
|
|
|
133.
|
Shively CA, Simons RJ, Passananti T, Dvorchik BH, Vesell ES. Dietary patterns and diurnal variations in aminopyrine disposition. Clin Pharmacol Ther. 1981 Jan; 29(1):65-73.
|
|
|
|
|
134.
|
Riester EF, Pantuck EJ, Pantuck CB, Passananti GT, Vesell ES, Conney AH. Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther. 1980 Sep; 28(3):384-91.
|
|
|
|
|
135.
|
Vesell ES. The influence of host factors on drug response. IV. Occupation. Ration Drug Ther. 1980 Jun; 14(6):1-5.
|
|
|
|
|
136.
|
Vesell ES. The influence of host factors on drug response. III. Diet. Ration Drug Ther. 1980 May; 14(5):1-6.
|
|
|
|
|
137.
|
Sultatos LG, Dvorchik BH, Vesell ES, Shand DG, Branch RA. Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine. Clin Pharmacokinet. 1980 May-Jun; 5(3):263-73.
|
|
|
|
|
138.
|
Spector R, Vesell ES. Training programs in clinical pharmacology. J Clin Pharmacol. 1980 May-Jun; 20(5-6 Pt 1):309-15.
|
|
|
|
|
139.
|
Vesell ES. Sounding board. Why are toxic reactions to drugs so often undetected initially? N Engl J Med. 1980 May 1; 302(18):1027-9.
|
|
|
|
|
140.
|
Vesell ES. The influence of host factors on drug response. II, Age. Ration Drug Ther. 1980 Apr; 14(4):1-7.
|
|
|
|
|
141.
|
Vesell ES. Elucidation of the pharmacokinetic interaction between acutely administered ethanol and benzodiazepines. J Lab Clin Med. 1980 Mar; 95(3):305-9.
|
|
|
|
|
142.
|
Vesell ES. Genetic and environmental factors affecting the metabolism of carcinogens. IARC Sci Publ. 1980; (27):23-40.
|
|
|
|
|
143.
|
Wood AW, Bartsch H, Fishbein L, Garattini S, Gielen J, Malaveille C, Roberfroid M, Teichman B, Vesell E. Basic requirements for in vitro metabolic activation systems in mutagenesis testing. IARC Monogr Eval Carcinog Risk Chem Hum Suppl. 1980; (2 Suppl):277-94.
|
|
|
|
|
144.
|
Sultatos LG, Vesell ES. Enhanced drug-metabolizing capacity within liver adjacent to human and rat liver tumors. Proc Natl Acad Sci U S A. 1980 Jan; 77(1):600-3.
|
|
|
|
|
145.
|
Loftin JP, Vesell ES. Interaction between sulindac and warfarin: different results in normal subjects and in an unusual patient with a potassium-losing renal tubular defect. J Clin Pharmacol. 1979 Nov-Dec; 19(11-12):733-42.
|
|
|
|
|
146.
|
Vesell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep; 26(3):275-86.
|
|
|
|
|
147.
|
Vesell ES, Shively CA, Passananti GT. Failure of cola nut chewing to alter antipyrine disposition in normal male subjects from a small town in South Central Pennsylvania. Clin Pharmacol Ther. 1979 Sep; 26(3):287-93.
|
|
|
|
|
148.
|
Vesell ES. The influence of host factors on drug response. I. Ethnic background. Ration Drug Ther. 1979 Aug; 13(8):1-7.
|
|
|
|
|
149.
|
Aungst BJ, Vesell ES, Shapiro JR. Unusual characteristics of the dose-dependent uptake of propylthiouracil by thyroid gland in vivo. Effects of thyrotropin, iodide or phenobarbital pretreatment. Biochem Pharmacol. 1979 May 1; 28(9):1479-84.
|
|
|
|
|
150.
|
Clemens TL, Hill RN, Bullock LP, Johnson WD, Sultatos LG, Vesell ES. Chloroform toxicity in the mouse: role of genetic factors and steroids. Toxicol Appl Pharmacol. 1979 Mar 30; 48(1 Pt 1):117-30.
|
|
|
|
|
151.
|
Sultatos LG, Vesell ES, Hepner GW. Heterogeneous response of hepatic mixed function oxidases to chronic phenobarbital administration. Biochem Pharmacol. 1979 Mar 15; 28(6):849-57.
|
|
|
|
|
152.
|
Vesell ES. Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response. Am J Med. 1979 Feb; 66(2):183-7.
|
|
|
|
|
153.
|
Marietta MP, Vesell ES, Hartman RD, Weisz J, Dvorchik BH. Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. J Pharmacol Exp Ther. 1979 Feb; 208(2):271-9.
|
|
|
|
|
154.
|
Hartshorn RD, Demers LM, Sultatos LG, Vesell ES, Lang CM, Hughes HC. Effects of chronic parenteral carbohydrate administration on hepatic drug metabolism in the rat. Pharmacology. 1979; 18(2):103-11.
|
|
|
|
|
155.
|
Shively CA, Simons RJ, Vesell ES. A sensitive gas-chromatographic assay using a nitrogen-phosphorus detector for determination of antipyrine and aminopyrine in biological fluids. Pharmacology. 1979; 19(5):228-36.
|
|
|
|
|
156.
|
Poley GE, Shively CA, Vesell ES. Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. Clin Pharmacol Ther. 1978 Dec; 24(6):726-32.
|
|
|
|
|
157.
|
Vesell ES. Intraspecies differences in frequency of genes directly affecting drug disposition: the individual factor in drug response. Pharmacol Rev. 1978 Dec; 30(4):555-63.
|
|
|
|
|
158.
|
Hepner GW, Vesell ES, Tantum KR. Reduced drug elimination in congestive heart failure. Studies using aminopyrine as a model drug. Am J Med. 1978 Aug; 65(2):371-6.
|
|
|
|
|
159.
|
Sultatos LG, Vesell ES, Hepner GW. Aminopyrine disposition: a sensitive index of acetaminophen-induced hepatocellular damage. Toxicol Appl Pharmacol. 1978 Jul; 45(1):177-89.
|
|
|
|
|
160.
|
Friedman Z, Whitman V, Maisels MJ, Berman W, Marks KH, Vesell ES. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol. 1978 May-Jun; 18(5-6):272-9.
|
|
|
|
|
161.
|
Shively CA, Gagliardi CL, Hartshorn RD, Vesell ES. Failure of hydrocortisone to alter acutely antipyrine disposition. Clin Pharmacol Ther. 1978 Apr; 23(4):408-13.
|
|
|
|
|
162.
|
Drouillard DD, Vesell ES, Dvorchik BH. Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. Clin Pharmacol Ther. 1978 Mar; 23(3):296-302.
|
|
|
|
|
163.
|
Doller HJ, Connor JD, Lock DR, Sloviter RS, Dvorchik BH, Vesell ES. Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor. Drug Metab Dispos. 1978 Mar-Apr; 6(2):164-8.
|
|
|
|
|
164.
|
Vesell ES. Twin studies in pharmacogenetics. Hum Genet Suppl. 1978; (1):19-30.
|
|
|
|
|
165.
|
Vesell ES. Disease as one of many variables affecting drug disposition and response: alterations of drug disposition in liver disease. Drug Metab Rev. 1978; 8(2):265-91.
|
|
|
|
|
166.
|
Valerino DM, Vesell ES, Stevens JT, Rudnick SL. Interaction of pargyline with rat hepatic microsomes. Pharmacology. 1978; 17(2):113-7.
|
|
|
|
|
167.
|
Wilding G, Paigen B, Vesell ES. Genetic control of interindividual variations in racemic warfarin binding to plasma and albumin of twins. Clin Pharmacol Ther. 1977 Dec; 22(6):831-42.
|
|
|
|
|
168.
|
Vesell ES, Shively CA, Passananti GT. Temporal variations of antipyrine half-life in man. Clin Pharmacol Ther. 1977 Dec; 22(6):843-52.
|
|
|
|
|
169.
|
Okuda T, Vesell ES, Plotkin E, Tarone R, Bast RC, Gelboin HV. Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res. 1977 Nov; 37(11):3904-11.
|
|
|
|
|
170.
|
Vesell ES. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 2):659-79.
|
|
|
|
|
171.
|
Vesell ES, Passananti GT. Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment. Environ Health Perspect. 1977 Oct; 20:159-82.
|
|
|
|
|
172.
|
Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med. 1977 Sep; 90(3):440-56.
|
|
|
|
|
173.
|
Wilding G, Feldhoff RC, Vesell ES. Concentration-dependent effects of fatty acids on warfarin binding to albumin. Biochem Pharmacol. 1977 Jun 15; 26(12):1143-6.
|
|
|
|
|
174.
|
Smith SJ, Leonard TB, Duceman BW, Vesell ES. Differential effects of phenobarbital and 3-methylcholanthrene on rat hepatic ribosomal precursor RNA. Biochem Pharmacol. 1977 May 15; 26(10):955-61.
|
|
|
|
|
175.
|
Hepner GW, Vesell ES. Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther. 1977 May; 21(5):620-6.
|
|
|
|
|
176.
|
Wilding G, Blumberg ES, Vesell ES. Reduced warfarin binding of albumin variants. Science. 1977 Mar 11; 195(4282):991-4.
|
|
|
|
|
177.
|
Hepner GW, Vesell ES. Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease. Clin Pharmacol Ther. 1976 Dec; 20(6):654-60.
|
|
|
|
|
178.
|
Vesell ES, Passananti GT, Hepner GW. Interaction between antipyrine and aminopyrine. Clin Pharmacol Ther. 1976 Dec; 20(6):661-9.
|
|
|
|
|
179.
|
Atlas SA, Vesell ES, Nebert DW. Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res. 1976 Dec; 36(12):4619-30.
|
|
|
|
|
180.
|
Smith SJ, Liu DK, Leonard TB, Duceman BW, Vesell ES. Phenobarbital-induced increases in methylation of ribosomal precursor ribonucleic acid. Mol Pharmacol. 1976 Sep; 12(5):820-31.
|
|
|
|
|
181.
|
Dvorchik BH, Vesell ES. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem. 1976 Jun; 22(6):868-78.
|
|
|
|
|
182.
|
Lang CM, Vesell ES. Environmental and genetic factors affecting laboratory animals: impact on biomedical research. Introduction. Fed Proc. 1976 Apr; 35(5):1123-4.
|
|
|
|
|
183.
|
Vesell ES, Lang CM, White WJ, Passananti GT, Hill RN, Clemens TL, Liu DK, Johnson WD. Environmental and genetic factors affecting the response of laboratory animals to drugs. Fed Proc. 1976 Apr; 35(5):1125-32.
|
|
|
|
|
184.
|
Smith SJ, Liu DK, Leonard TB, Duceman BW, Vesell ES. Molecular biology of phenobarbital actions and interactions. Ann N Y Acad Sci. 1976; 281:372-83.
|
|
|
|
|
185.
|
Berlin CM, Stackman JM, Vesell ES. Quinine-induced alterations in drug disposition. Clin Pharmacol Ther. 1975 Dec; 18(06):670-9.
|
|
|
|
|
186.
|
Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975 Nov; 83(5):632-8.
|
|
|
|
|
187.
|
Hill RN, Clemens TL, Liu DK, Vesell ES, Johnson WD. Genetic control of chloroform toxicity in mice. Science. 1975 Oct 10; 190(4210):159-61.
|
|
|
|
|
188.
|
Shively CA, Vesell ES. Temporal variations in acetaminophen and phenacetin half-life in man. Clin Pharmacol Ther. 1975 Oct; 18(4):413-24.
|
|
|
|
|
189.
|
Vesell ES, Passananti GT, Glenwright PA, Dvorchik BH. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther. 1975 Sep; 18(3):259-72.
|
|
|
|
|
190.
|
Vesell ES, Passananti GT, Johnson AO. Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol. 1975 Jul; 15(7):486-95.
|
|
|
|
|
191.
|
Reidenberg MM, Vesell ES. Unaltered metabolism of antipyrine and tolbutamide in fasting man. Clin Pharmacol Ther. 1975 Jun; 17(6):650-6.
|
|
|
|
|
192.
|
Elin RJ, Vesell ES, Wolff SM. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther. 1975 Apr; 17(4):447-57.
|
|
|
|
|
193.
|
Vesell ES. Pharmacogenetics. Biochem Pharmacol. 1975 Feb 15; 24(4):445-50.
|
|
|
|
|
194.
|
Passananti GT, Shively CA, Vesell ES. Orally administered dimethyl sulfoxide: its effects on blood concentrations of salicyclic acid, sulfanilamide, and warfarin. Ann N Y Acad Sci. 1975 Jan 27; 243:311-6.
|
|
|
|
|
195.
|
Vesell ES, Passananti GT, Aurori KC. Anomalous results of studies on drug interaction in man. I. Nortriptyline and antipyrine. Pharmacology. 1975; 13(2):101-11.
|
|
|
|
|
196.
|
Vesell ES, Passananti GT. Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin. Pharmacology. 1975; 13(2):112-27.
|
|
|
|
|
197.
|
Vesell ES. Pharmacogenetics--the individual factor in drug response. Triangle. 1975; 14(3-4):125-30.
|
|
|
|
|
198.
|
Vesell ES, Passananti T, Glenwright PA. Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine. Pharmacology. 1975; 13(6):481-91.
|
|
|
|
|
199.
|
Hepner GW, Vesell ES. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. Am J Dig Dis. 1975 Jan; 20(1):9-12.
|
|
|
|
|
200.
|
Vesell ES, Shapiro JR, Passananti T, Jorgensen H, Shively CA. Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther. 1975 Jan; 17(1):48-56.
|
|
|
|
|
201.
|
Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med. 1974 Dec 26; 291(26):1384-8.
|
|
|
|
|
202.
|
Haines CF, Mahajan DK, Miljkovc D, Miljkovic M, Vesell ES. Radioimmunoassay of plasma nicotine in habituated and naive smokers. Clin Pharmacol Ther. 1974 Dec; 16(6):1083-9.
|
|
|
|
|
203.
|
Andreasen PB, Vesell ES. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther. 1974 Dec; 16(6):1059-65.
|
|
|
|
|
204.
|
Aurori KC, Vesell ES. Comparative stimulatory effects of four phenothiazines on hepatic microsomal enzymes. Drug Metab Dispos. 1974 Nov-Dec; 2(6):566-72.
|
|
|
|
|
205.
|
Vesell ES. Proceedings: Genetic factors affecting response to psychopharmacological agents. Psychopharmacol Bull. 1974 Oct; 10(4):68-9.
|
|
|
|
|
206.
|
Valerino DM, Vesell ES, Aurori KC, Johnson AO. Effects of various barbiturates on hepatic microsomal enzymes. A comparative study. Drug Metab Dispos. 1974 Sep-Oct; 2(5):448-57.
|
|
|
|
|
207.
|
Vesell ES. Polygenic factors controlling drug response. Med Clin North Am. 1974 Sep; 58(5):951-63.
|
|
|
|
|
208.
|
Valerino DM, Soliman MR, Aurori KC, Tripp SL, Wykes AA, Vesell ES. Studies on the interaction of several boron hydrides with liver microsomal enzymes. Toxicol Appl Pharmacol. 1974 Sep; 29(3):358-66.
|
|
|
|
|
209.
|
Vesell ES. Factors causing interindividual variations of drug concentrations in blood. Clin Pharmacol Ther. 1974 Jul; 16(1):135-48.
|
|
|
|
|
210.
|
Vesell ES, Shively CA. Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjects. Science. 1974 Apr 26; 184(4135):466-8.
|
|
|
|
|
211.
|
Smith SJ, Jacob ST, Liu DK, Duceman B, Vesell ES. Further studies on post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. Mol Pharmacol. 1974 Mar; 10(2):248-56.
|
|
|
|
|
212.
|
Crew MC, Vesell ES, Passananti GT, Gala RL, Di Carlo FJ. Studies on the metabolism in man of oxisuran, a differential immunosuppressive drug. Clin Pharmacol Ther. 1973 Nov-Dec; 14(6):1013-21.
|
|
|
|
|
213.
|
Fritz PJ, White EL, Pruitt KM, Vesell ES. Lactate dehydrogenase isozymes. Turnover in rat heart, skeletal muscle, and liver. Biochemistry. 1973 Oct 9; 12(21):4034-9.
|
|
|
|
|
214.
|
Valerino DM, Vesell ES, Johnson AO, Aurori KC. Effects of various centrally active drugs on hepatic microsomal enzymes: a comparative study. Drug Metab Dispos. 1973 Sep-Oct; 1(5):669-78.
|
|
|
|
|
215.
|
Vesell ES, Lang CM, White WJ, Passananti GT, Tripp SL. Hepatic drug metabolism in rats: impairment in a dirty environment. Science. 1973 Mar 2; 179(4076):896-7.
|
|
|
|
|
216.
|
Vesell ES, Lee CJ, Passananti GT, Shively CA. Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. Pharmacology. 1973; 10(6):317-28.
|
|
|
|
|
217.
|
Vesell ES. Advances in pharmacogenetics. Prog Med Genet. 1973; 9:291-367.
|
|
|
|
|
218.
|
Vesell ES, Passananti GT. Inhibition of drug metabolism in man. Drug Metab Dispos. 1973 Jan-Feb; 1(1):402-10.
|
|
|
|
|
219.
|
Vesell ES. Pharmacogenetics. N Engl J Med. 1972 Nov 2; 287(18):904-9.
|
|
|
|
|
220.
|
Smith SJ, Hill RN, Gleeson RA, Vesell ES. Evidence for post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. Mol Pharmacol. 1972 Nov; 8(6):691-700.
|
|
|
|
|
221.
|
Vesell ES. Genetic and environmental factors affecting drug response in man. Fed Proc. 1972 Jul-Aug; 31(4):1253-69.
|
|
|
|
|
222.
|
Vesell ES. Ethanol metabolism: regulation by genetic factors in normal volunteers under a controlled environment and the effect of chronic ethanol administration. Ann N Y Acad Sci. 1972 May 25; 197:79-88.
|
|
|
|
|
223.
|
Cohn CK, Vesell ES, Axelrod J. Studies of a methionine-activating enzyme. Biochem Pharmacol. 1972 Mar 15; 21(6):803-9.
|
|
|
|
|
224.
|
Vesell ES, Passananti GT, Viau JP, Epps JE, Di Carlo FJ. Effects of chronic prazepam administration on drug metabolism in man and rat. Pharmacology. 1972; 7(3):197-206.
|
|
|
|
|
225.
|
Ross SB, Weinshilboum R, Molinoff PB, Vesell ES, Axelrod J. Electrophoretic properties of dopamine -hydroxylase in several tissues from three species. Mol Pharmacol. 1972 Jan; 8(1):50-8.
|
|
|
|
|
226.
|
Chignell CF, Vesell ES, Starkweather DK, Berlin CM. The binding of sulfaphenazole to fetal, neonatal, and adult human plasma albumin. Clin Pharmacol Ther. 1971 Nov-Dec; 12(6):897-901.
|
|
|
|
|
227.
|
Spector S, Vesell ES. Disposition of morphine in man. Science. 1971 Oct 22; 174(4007):421-2.
|
|
|
|
|
228.
|
Vesell ES, Passananti GT, Lee CH. Impairment of drug metabolism by disulfiram in man. Clin Pharmacol Ther. 1971 Sep-Oct; 12(5):785-92.
|
|
|
|
|
229.
|
Vesell ES, Ng L, Passananti GT, Chase TN. Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet. 1971 Aug 14; 2(7720):370.
|
|
|
|
|
230.
|
Vesell ES, Passananti GT, Greene FE, Page JG. Genetic control of drug levels and of the induction of drug-metabolizing enzymes in man: individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism. Ann N Y Acad Sci. 1971 Jul 6; 179:752-73.
|
|
|
|
|
231.
|
Cascorbi HF, Vesell ES, Blake DA, Helrich M. Halothane biotransformation in man. Ann N Y Acad Sci. 1971 Jul 6; 179:244-8.
|
|
|
|
|
232.
|
Fraser IM, Tilton BE, Vesell ES. Effects of some metabolites of hemolytic drugs on young and old, normal and G-6-PD-deficient human erythrocytes. Ann N Y Acad Sci. 1971 Jul 6; 179:644-53.
|
|
|
|
|
233.
|
Wuntch T, Chen RF, Vesell ES. Lactate dehydrogenase isozymes: further kinetic studies at high enzyme concentration. Science. 1971 Apr 2; 172(3978):45.
|
|
|
|
|
234.
|
Fritz PJ, White EL, Vesell ES, Pruitt KM. New theory of the control of protein concentrations in animal cells. Nat New Biol. 1971 Mar 24; 230(12):119-22.
|
|
|
|
|
235.
|
Vesell ES, Page JG, Passananti GT. Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther. 1971 Mar-Apr; 12(2):192-201.
|
|
|
|
|
236.
|
Fraser IM, Tilton BE, Vesell ES. Alterations in normal and G-6-PD deficient human erythrocytes of various ages after exposure to metabolites of hemolytic drugs. Pharmacology. 1971; 5(3):173-87.
|
|
|
|
|
237.
|
Cascorbi HF, Vesell ES, Blake DA, Helrich M. Genetic and environmental influence on halothane metabolism in twins. Clin Pharmacol Ther. 1971 Jan-Feb; 12(1):50-5.
|
|
|
|
|
238.
|
Vesell ES, Passananti GT, Greene FE. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med. 1970 Dec 31; 283(27):1484-8.
|
|
|
|
|
239.
|
Fritz PJ, Morrison WJ, White EL, Vesell ES. Comparative study of methods for quantitation of lactate dehydrogenase isozymes. Anal Biochem. 1970 Aug; 36(2):443-53.
|
|
|
|
|
240.
|
Wuntch T, Chen RF, Vesell ES. Lactate dehydrogenase isozymes: further kinetic studies at high enzyme concentration. Science. 1970 Jul 31; 169(3944):480-1.
|
|
|
|
|
241.
|
Page JG, Kessler RM, Vesell ES. Strain differences in uptake, pool size and turnover rate of norepinephrine in hearts of mice. Biochem Pharmacol. 1970 Apr; 19(4):1381-6.
|
|
|
|
|
242.
|
Wuntch T, Chen RF, Vesell ES. Lactate dehydrogenase isozymes: kinetic properties at high enzyme concentrations. Science. 1970 Jan 2; 167(3914):63-5.
|
|
|
|
|
243.
|
Axelrod J, Vesell ES. Heterogeneity of N-and O-methyltransferases. Mol Pharmacol. 1970 Jan; 6(1):78-84.
|
|
|
|
|
244.
|
Vesell ES, Page JG. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969 Dec; 48(12):2202-9.
|
|
|
|
|
245.
|
Wuntch T, Vesell ES, Chen RF. Studies on rates of abortive ternary complex formation of lactate dehydrogenase isozymes. J Biol Chem. 1969 Nov 25; 244(22):6100-4.
|
|
|
|
|
246.
|
Vesell ES. Multiple molecular forms of enzymes. Surg Clin North Am. 1969 Jun; 49(3):571-5.
|
|
|
|
|
247.
|
Page JG, Vesell ES. Hepatic drug metabolism in ten strains of Norway rat before and after pretreatment with phenobarbital. Proc Soc Exp Biol Med. 1969 May; 131(1):256-61.
|
|
|
|
|
248.
|
Fritz PJ, Vesell ES, White EL, Pruitt KM. The roles of synthesis and degradation in determining tissue concentrations of lactate dehydrogenase-5. Proc Natl Acad Sci U S A. 1969 Feb; 62(2):558-65.
|
|
|
|
|
249.
|
Page JG, Vesell ES. Sex and strain differences in basal and induced aniline hydroxylase and ethylmorphine N-demethylase activities from domestic and wild rats. Pharmacology. 1969; 2(6):321-36.
|
|
|
|
|
250.
|
Vesell ES. Recent progress in pharmacogenetics. Adv Pharmacol. 1969; 7:1-52.
|
|
|
|
|
251.
|
Vesell ES. Recent progress in pharmacogenetics. Adv Pharmacol Chemother. 1969; 7:1-52.
|
|
|
|
|
252.
|
Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest. 1968 Dec; 47(12):2657-63.
|
|
|
|
|
253.
|
Fraser IM, Vesell ES. Effects of drugs and drug metabolites on erythrocytes from normal and glucose-6-phosphate dehydrogenase-deficient individuals. Ann N Y Acad Sci. 1968 Jul 31; 151(2):777-94.
|
|
|
|
|
254.
|
Vesell ES. Genetic and environmental factors affecting hexobarbital metabolism in mice. Ann N Y Acad Sci. 1968 Jul 31; 151(2):900-12.
|
|
|
|
|
255.
|
Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science. 1968 Jul 5; 161(3836):72-3.
|
|
|
|
|
256.
|
Fraser IM, Vesell ES. Effects of metabolites of primaquine and acetanilid on normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. J Pharmacol Exp Ther. 1968 Jul; 162(1):155-65.
|
|
|
|
|
257.
|
Vesell ES. Multiple molecular forms of enzymes. Introduction. Ann N Y Acad Sci. 1968 Jun 14; 151(1):5-13.
|
|
|
|
|
258.
|
Vesell ES, Yielding KL. Protection of lactate dehydrogenase isozymes from heat inactivation and enzymatic degradation. Ann N Y Acad Sci. 1968 Jun 14; 151(1):678-89.
|
|
|
|
|
259.
|
Vesell ES, Fritz PJ, White EL. Effects of buffer,pH, ionic strength and temperatures on lactate dehydrogenase isozymes. Biochim Biophys Acta. 1968 Jun 4; 159(2):236-43.
|
|
|
|
|
260.
|
Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science. 1968 Mar 29; 159(3822):1479-80.
|
|
|
|
|
261.
|
Wurtman RJ, Axelrod J, Vesell ES, Ross GT. Species differences in inducibility of phenylethanolamine-N-methyl transferase. Endocrinology. 1968 Mar; 82(3):584-90.
|
|
|
|
|
262.
|
Vesell ES. Factors altering the responsiveness of mice to hexobarbital. Pharmacology. 1968; 1(2):81-97.
|
|
|
|
|
263.
|
Vesell ES. Induction of drug-metabolizing enzymes in liver microsomes of mice and rats by softwood bedding. Science. 1967 Sep 1; 157(3792):1057-8.
|
|
|
|
|
264.
|
Vesell ES, Yielding KL. Effects of pH, ionic strength, and metabolic intermediates on the rates of heat inactivation of lactate dehydrogenase isozymes. Proc Natl Acad Sci U S A. 1966 Oct; 56(4):1317-24.
|
|
|
|
|
265.
|
Vesell ES. pH dependence of lactate dehydrogenase isozyme inhibition by substrate. Nature. 1966 Apr 23; 210(5034):421-2.
|
|
|
|
|
266.
|
Vesell ES, Pool PE. Lactate and pyruvate concentrations in exercised ischemic canine muscle: relationship of tissue substrate level to lactate dehydrogenase isozyme pattern. Proc Natl Acad Sci U S A. 1966 Apr; 55(4):756-62.
|
|
|
|
|
267.
|
Vesell ES. Lactate dehydrogenase isozyme patterns of human platelets and bovine lens fibers. Science. 1965 Dec 24; 150(3704):1735-7.
|
|
|
|
|
268.
|
Vesell ES. Lactate dehydrogenase Isozymes: substrate inhibition in various human tissues. Science. 1965 Dec 17; 150(3703):1590-3.
|
|
|
|
|
269.
|
Vesell ES. Formation of human lactate dehydrogenase isozyme patterns in vitro. Proc Natl Acad Sci U S A. 1965 Jul; 54(1):111-7.
|
|
|
|
|
270.
|
VESELL ES. POLYMORPHISM OF HUMAN LACTATE DEHYDROGENASE ISOZYMES. Science. 1965 May 21; 148(3673):1103-5.
|
|
|
|
|
271.
|
Vesell ES. Genetic control of isozyme patterns in human tissues. Prog Med Genet. 1965; 4:128-75.
|
|
|
|
|
272.
|
VESELL ES, BRODY IA. BIOLOGICAL APPLICATIONS OF LACTIC DEHYDROGENASE ISOZYMES: CERTAIN METHODOLOGICAL CONSIDERATIONS. Ann N Y Acad Sci. 1964 Dec 28; 121:544-59.
|
|
|
|
|
273.
|
VESELL ES, PHILIP J. ISOZYMES OF LACTIC DEHYDROGENASE: SEQUENTIAL ALTERATIONS DURING DEVELOPMENT. Ann N Y Acad Sci. 1963 Dec 30; 111:243-57.
|
|
|
|
|
274.
|
VESELL ES, OSTERLAND KC, BEARN AG, KUNKEL HG. Isozymes of lactice dehydrogenase; their alterations in arthritic synovial fluid and sera. J Clin Invest. 1962 Nov; 41:2012-9.
|
|
|
|
|
275.
|
VESELL ES, PHILIP J, BEARN AG. Comparative studies of the isozymes of lactic dehydrogenase in rabbit and man. Observations during development and in tissue culture. J Exp Med. 1962 Nov 1; 116:797-806.
|
|
|
|
|
276.
|
VESELL ES, BEARN AG. Localization of a lactice dehydrogenase isozyme in nuclei of young cells in the erythrocyte series. Proc Soc Exp Biol Med. 1962 Oct; 111:100-4.
|
|
|
|
|
277.
|
VESELL ES. Effect of dilution on the lactic dehydrogenase isozyme pattern obtained in the starch gel. Nature. 1962 Aug 4; 195:497-8.
|
|
|
|
|
278.
|
PHILIP J, VESELL ES. Sequential alterations of lactic dehydrogenase isozymes during embryonic development and in tissue culture. Proc Soc Exp Biol Med. 1962 Jul; 110:582-5.
|
|
|
|
|
279.
|
VESELL ES, BEARN AG. Variations in the lactic dehydrogenase of vertebrate erythrocytes. J Gen Physiol. 1962 Jan; 45:553-65.
|
|
|
|
|
280.
|
VESELL ES. Significance of the heterogeneity of lactic dehydrogenase activity in human tissues. Ann N Y Acad Sci. 1961 Nov 2; 94:877-89.
|
|
|
|
|
281.
|
CICCARELLI EC, VESELL ES. Laurence-Moon-Biedl syndrome. Report of an unusual family. Am J Dis Child. 1961 Apr; 101:519-24.
|
|
|
|
|
282.
|
VESELL ES, BEARN AG. Isozymes of lactic dehydrogenase in human tissues. J Clin Invest. 1961 Mar; 40:586-91.
|
|
|
|
|
283.
|
VESELL ES. Symphalangism, strabismus and hearing loss in mother and daughter. N Engl J Med. 1960 Oct 27; 263:839-42.
|
|
|
|
|
284.
|
VESELL ES, PALMERIO CF, FRANK ED. Serum lactic dehydrogenase activity in experimental endotoxic shock. Proc Soc Exp Biol Med. 1960 Jul; 104:403-5.
|
|
|
|
|
285.
|
VESELL ES, FELDMAN MP, FRANK ED. Plasma lactic dehydrogenase activity in experimental hemorragic shock. Proc Soc Exp Biol Med. 1959 Aug-Sep; 101:644-8.
|
|
|
|
|
286.
|
VESELL ES. Urinary test for a metabolite of prochlorperazine. N Engl J Med. 1959 May 21; 260(21):1078.
|
|
|
|
|
287.
|
VESELL ES, BEARN AG. The heterogeneity of lactic and malic dehydrogenase. Ann N Y Acad Sci. 1958 Oct 13; 75(1):286-91.
|
|
|
|
|
288.
|
VESELL ES, BEARN AG. Observations on the heterogeneity of malic and lactic dehydrogenase in human serum and red blood cells. J Clin Invest. 1958 May; 37(5):672-7.
|
|
|
|
|
289.
|
BEARN AG, VESELL ES. Localization of lactic acid dehydrogenase activity in serum fractions. Proc Soc Exp Biol Med. 1957 Jan; 94(1):96-9.
|
|
|
|